Apex Biotechnology (TPE:1733) Cash-to-Debt : 3.60 (As of Dec. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Apex Biotechnology Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Apex Biotechnology's cash to debt ratio for the quarter that ended in Dec. 2024 was 3.60.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Apex Biotechnology could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Apex Biotechnology's Cash-to-Debt or its related term are showing as below:

TPE:1733' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.84 Med: 1.46 Max: 3.6
Current: 3.6

During the past 13 years, Apex Biotechnology's highest Cash to Debt Ratio was 3.60. The lowest was 0.84. And the median was 1.46.

TPE:1733's Cash-to-Debt is ranked worse than
59.2% of 1483 companies
in the Biotechnology industry
Industry Median: 7.71 vs TPE:1733: 3.60

Apex Biotechnology Cash-to-Debt Historical Data

The historical data trend for Apex Biotechnology's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Apex Biotechnology Cash-to-Debt Chart

Apex Biotechnology Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

1.44

1.84

1.63

2.46

3.60

Apex Biotechnology Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial															2.46	2.86	2.68	2.96	3.60

Competitive Comparison of Apex Biotechnology's Cash-to-Debt

For the Biotechnology subindustry, Apex Biotechnology's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apex Biotechnology's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apex Biotechnology's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Apex Biotechnology's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Apex Biotechnology Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Apex Biotechnology's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	598.784	/	(52.233	+	113.929)
	=	3.60

Apex Biotechnology's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	598.784	/	(52.233	+	113.929)
	=	3.60

Apex Biotechnology (TPE:1733) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Apex Biotechnology Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Apex Biotechnology's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Apex Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apex Biotechnology Corp (TPE:1733) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.7, Li-Hsin 5th Road, Hsinchu Science Park, Hsinchu, TWN, 30078

Website

https://www.apexbio.com

Apex Biotechnology Corp engages mainly in the research, development, production, manufacturing, and selling of biochemical testing instruments and detection strips, and the trade of products and components relevant to the core business. Its products offer Diabetes Care, Home Diagnostics, and Point-of-Care Clinical and Laboratory. Its product offerings include Eclipse plus multipurpose analyzer, Glucosure HT blood glucose monitoring system, and HemoSmart GOLD hemoglobin screening system among others. Company operates in Taiwan, USA, Italy, Austria, China , Others. Majority of revenue is from USA.

Apex Biotechnology Headlines

No Headlines